Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 11;14(1):169.
doi: 10.1186/s13195-022-01103-7.

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus

John T O'Brien  1   2 , Leonidas Chouliaras  3 , Janet Sultana  4 , John-Paul Taylor  5 , Clive Ballard  4 ; RENEWAL Study Group
Collaborators, Affiliations
Review

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus

John T O'Brien et al. Alzheimers Res Ther. .

Abstract

Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson's disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.

PubMed Disclaimer

Conflict of interest statement

JOB has acted as a consultant for TauRx, Eisai, Novo Nordisk, Biogen and GE Healthcare and received grant support from Avid/ Lilly, MSD and Alliance Medical. J-PT has acted as a consultant for Sosei Heptares, Kyoma-Kirin and received speaker fees from GE Healthcare.

FBPS has acted as a consultant for BiogenAbbVie and received speaker Lundbeck. DG has received grant funding from Parkinson’s UK, honoraria from BIAL Pharma, AbbVie, Britannia Pharmaceuticals and consultancy fees from Roche and Biogen; FB is or was the national coordinator for France of clinical trials on DLB (Headway-DLB, Axovant; Delphia, Eisai) and AD (Graduate and PostGraduate, Roche).

References

    1. Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44:673–683. - PubMed
    1. Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor J-P, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10:19. - PMC - PubMed
    1. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;66:1455. - PMC - PubMed
    1. Wu Y-T, Clare L, Hindle JV, Nelis SM, Martyr A, Matthews FE, et al. Dementia subtype and living well: results from the Improving the experience of Dementia and Enhancing Active Life (IDEAL) study. BMC Med. 2018;16:140. - PMC - PubMed
    1. Price A, Farooq R, Yuan J-M, Menon VB, Cardinal RN, O’Brien JT. Mortality in dementia with Lewy bodies compared with Alzheimer’s dementia: a retrospective naturalistic cohort study. BMJ Open. 2017;7:e017504. - PMC - PubMed

Publication types